Costs/benefits outside healthcare sector relevant in economic evaluations
- PDF / 167,032 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 74 Downloads / 188 Views
1
Costs/benefits outside healthcare sector relevant in economic evaluations Education and criminal justice costs and benefits are relevant in economic evaluations of interventions targeting mental and behavioural disorders (MBDs), report researchers from The Netherlands. The researchers used online best-worst scaling object case surveys among health economists and health technology assessment experts to assess their opinions and attitudes regarding the relative importance of education and criminal justice intersectoral costs and benefits (ICBs) in economic evaluations. The analysis of data from 39 respondents showed that education and criminal justice ICBs were considered relevant for inclusion in economic evaluations by the majority of respondents (29 and 31 respondents, respectively). Interestingly, the majority of the respondents who found ICBs relevant (68%) had never included them in economic evaluations. The most important education ICBs were ’special education school attendance’, ’absenteeism from school’ and ’reduced school attainment’. The most important criminal justice ICBs were ’decreased chance of committing a crime as a consequence/effect of mental health programmes/interventions’, ’jail and prison expenditures’ and ’long-term pain and suffering of victims/victimisation’. "The ranking of the most important education and criminal justice ICBs identified in this study can help select relevant ICBs for developing measurement and valuation tools for the inclusion in economic evaluations in the domain of MBDs," conclude the researchers. Pokhilenko I, et al. The Relative Importance of Education and Criminal Justice Costs and Benefits in Economic Evaluations: A Best-Worst Scaling Experiment. PharmacoEconomics : 7 Oct 2020. Available from: URL: https://doi.org/10.1007/s40273-020-00966-8
1173-5503/20/0864-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803508098
PharmacoEconomics & Outcomes News 17 Oct 2020 No. 864
Data Loading...
